Clinical Transformation of Organoid Model to Predict the Efficacy of GC in the Treatment of Intrahepatic Cholangiocarcinoma

Launched by CHENGJUN SUI,MD · Nov 30, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new way to predict how well a specific chemotherapy treatment, called GC, will work for patients with intrahepatic cholangiocarcinoma (ICC), a type of cancer that affects the bile ducts in the liver. Researchers will create small, lab-grown versions of patients' tumors, known as organoids, from samples taken during a biopsy. These organoids will help them understand how tumors react to the chemotherapy and identify any genetic factors that might make the cancer resistant to treatment. The goal is to develop a personalized approach to treatment, ensuring that each patient receives the most effective therapy based on their unique tumor characteristics.

To be eligible for this trial, patients need to be between 18 and 80 years old and have a confirmed diagnosis of intrahepatic cholangiocarcinoma. They must also be able to provide written consent and have a biopsy sample available. Participants can expect to contribute to important research that could improve treatment options for future patients with this challenging cancer. It's important to note that the trial is not yet recruiting participants, so interested individuals should keep an eye out for updates.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - Histologically confirmed intrahepatic cholangiocarcinoma They are between 18 and 80 years old Written informed and signed consent form Biopsy sample of the intrahepatic bile duct
• Exclusion Criteria:
• • - Under 18, over 80 Informed consent cannot be given Biopsy samples were not available